Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tracon Pharma Acquires US Rights to 3D Medicines/Alphamab PD-L1

publication date: Dec 20, 2019

San Diego's Tracon Pharma will collaborate with 3D Medicines (Beijing) and Jiangsu Alphamab Biopharma to develop envafolimab, a PD-L1, for soft tissue sarcoma in North America. Tracon will be responsible for the clinical trials and commercialization of the candidate. The company believes envafolimab, which is injected subcutaneously without the need for an adjuvant, has the potential to be a best-in-class PD-L1 inhibitor. Because PD-1 and PD-L1 candidates have shown activity in soft tissue sarcoma subtypes, including undifferentiated pleomorphic sarcoma (UPS), Tracon will begin a US envafolimab trial in UPS patients next year. More details....

Stock Symbol: (NSDQ: TCON)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital